Skip to main content

Table 3 Platelet Reactivity Index (PRI) in the two groups during the 1-year study

From: Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study

 

PRI (mean ± SD, %)

3 months

6 months

9 months

12 months

P-value*

after randomisation

Control group

68.4 ± 17.2

48.5 ± 13.2

51.6 ± 19.8

65.3 ± 17.2

>0.05

VASP-guided group

73.5 ± 12.7

32.3 ± 4.9

35.5 ± 6.7

29.8 ± 7.3

0.001

P-value#

0.4

0.04

<0.001

0.03

<0.001

  1. VASP vasodilator-stimulated phosphoprotein
  2. *comparison between 3, 6, 9, and 12 months
  3. #comparison between the control group and VASP-guided group